Managing Diabetes When a Patient Declines Insulin

Initial Response to Insulin Refusal

The American Diabetes Association recommends that if a patient declines insulin therapy, intensify non-insulin agents with triple combination therapy using metformin plus two additional agents with complementary mechanisms, while simultaneously providing education and counseling to overcome insulin reluctance 1, 2
Most patients express reluctance to beginning injectable therapy, but if the practitioner feels that such a transition is important, encouragement and education can usually overcome such reticence, according to the American Diabetes Association 1
Address specific fears about insulin including concerns about hypoglycemia, weight gain, injection pain, and perceived disease severity, as suggested by the American Diabetes Association 1

If the patient presents with severe hyperglycemia with catabolic features, insulin therapy is mandatory and refusal should trigger intensive counseling about life-threatening risks, as recommended by the American College of Physicians and the American Diabetes Association 2, 3
In less severe hyperglycemia, there is a narrow window to attempt intensive non-insulin therapy while continuing insulin education, according to the American Diabetes Association 1, 2

Add a third non-insulin agent to the existing regimen, selecting agents with complementary mechanisms of action, as recommended by the American Diabetes Association 1
Alternative triple combinations can include metformin, a DPP-4 inhibitor, and a sulfonylurea, though this carries higher hypoglycemia risk, according to the American Diabetes Association 2

Monitor the patient closely and promptly reconsider the approach if unsuccessful, as recommended by the American Diabetes Association 1
Reassess HbA1c every 3 months; if HbA1c remains ≥8.5% after 3 months of triple therapy, insulin becomes essential, according to the American College of Physicians and the American Diabetes Association 1, 4

At HbA1c levels ≥8.5%, it becomes unlikely that additional non-insulin agents will provide sufficient benefit, and insulin should be strongly favored, as recommended by the American Diabetes Association 1
Prolonged uncontrolled hyperglycemia increases the risk of long-term complications and should be avoided even if it means more intensive counseling about insulin, according to the American Diabetes Association 1

When the patient agrees to insulin, begin with a single injection of basal insulin at a low dose, which is the most convenient strategy, as recommended by the American Diabetes Association and the American College of Physicians 1, 3
Continue metformin and potentially one other non-insulin agent to reduce insulin requirements and minimize weight gain, according to the American College of Physicians 3
Teach patients to self-titrate their insulin dose, adding 1-2 units once or twice weekly if fasting glucose levels remain above target, as recommended by the American Diabetes Association 1

La insulinoterapia es obligatoria cuando se presentan características catabólicas o si se demuestra cetonuria, lo que refleja una deficiencia profunda de insulina, según Diabetes Care 5
En la diabetes tipo 1, existe una deficiencia absoluta de insulina que requiere terapia de reemplazo para prevenir complicaciones agudas y crónicas, según Diabetes Care 6
No existen alternativas aprobadas para reemplazar la insulina en diabetes tipo 1, según Diabetes Care 6

La insulina sigue siendo el pilar fundamental del tratamiento para la diabetes tipo 1 y no puede ser reemplazada por dapagliflozina, según Diabetes Care 6
Si el paciente rechaza absolutamente la insulina, es crucial enfatizar los riesgos potencialmente mortales de esta decisión y ofrecer apoyo psicológico para abordar las barreras al uso de insulina, según Diabetes Care 5